Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.
Mehta PP, Kung PP, Yamazaki S, Walls M, Shen A, Nguyen L, Gehring MR, Los G, Smeal T, Yin MJ. Mehta PP, et al. Among authors: walls m. Cancer Lett. 2011 Jan 1;300(1):30-9. doi: 10.1016/j.canlet.2010.09.002. Cancer Lett. 2011. Retraction in: Cancer Lett. 2018 May 28;422:132. doi: 10.1016/j.canlet.2018.03.019. PMID: 20926183 Retracted.
Targeting the mTOR pathway in tumor malignancy.
Cheng H, Walls M, Baxi SM, Yin MJ. Cheng H, et al. Among authors: walls m. Curr Cancer Drug Targets. 2013 Mar;13(3):267-77. doi: 10.2174/1568009611313030005. Curr Cancer Drug Targets. 2013. PMID: 23297825 Review.
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Walls M, Baxi SM, Mehta PP, Liu KK, Zhu J, Estrella H, Li C, Zientek M, Zong Q, Smeal T, Yin MJ. Walls M, et al. Clin Cancer Res. 2014 Feb 1;20(3):631-43. doi: 10.1158/1078-0432.CCR-13-1663. Epub 2013 Nov 15. Clin Cancer Res. 2014. Retraction in: Clin Cancer Res. 2017 Aug 1;23(15):4523. doi: 10.1158/1078-0432.CCR-17-1502. PMID: 24240111 Retracted.
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
Liu KK, Zhu J, Smith GL, Yin MJ, Bailey S, Chen JH, Hu Q, Huang Q, Li C, Li QJ, Marx MA, Paderes G, Richardson PF, Sach NW, Walls M, Wells PA, Baxi S, Zou A. Liu KK, et al. Among authors: walls m. ACS Med Chem Lett. 2011 Sep 19;2(11):809-13. doi: 10.1021/ml200126j. eCollection 2011 Nov 10. ACS Med Chem Lett. 2011. PMID: 24900269 Free PMC article.
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M. Cheng H, et al. Among authors: walls m. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. doi: 10.1021/ml300309h. eCollection 2013 Jan 10. ACS Med Chem Lett. 2012. PMID: 24900568 Free PMC article.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H, Nair SK, Murray BW, Almaden C, Bailey S, Baxi S, Behenna D, Cho-Schultz S, Dalvie D, Dinh DM, Edwards MP, Feng JL, Ferre RA, Gajiwala KS, Hemkens MD, Jackson-Fisher A, Jalaie M, Johnson TO, Kania RS, Kephart S, Lafontaine J, Lunney B, Liu KK, Liu Z, Matthews J, Nagata A, Niessen S, Ornelas MA, Orr ST, Pairish M, Planken S, Ren S, Richter D, Ryan K, Sach N, Shen H, Smeal T, Solowiej J, Sutton S, Tran K, Tseng E, Vernier W, Walls M, Wang S, Weinrich SL, Xin S, Xu H, Yin MJ, Zientek M, Zhou R, Kath JC. Cheng H, et al. Among authors: walls m. J Med Chem. 2016 Mar 10;59(5):2005-24. doi: 10.1021/acs.jmedchem.5b01633. Epub 2016 Jan 28. J Med Chem. 2016. PMID: 26756222
Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Boloor A, Hanway D, Joshi M, Winn DT, Mendez G, Walls M, Wei P, Qian F, Zhang X, Zhang Y, Hepperle ME, Li X, Campbell DA, Betancort JM. Boloor A, et al. Among authors: walls m. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5708-11. doi: 10.1016/j.bmcl.2009.08.017. Epub 2009 Aug 8. Bioorg Med Chem Lett. 2009. PMID: 19713109
Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth.
Huang X, Magnus J, Kaimal V, Karmali P, Li J, Walls M, Prudente R, Sung E, Sorourian M, Lee R, Davis S, Yang X, Estrella H, Lee EC, Chau BN, Pavlicek A, Zabludoff S. Huang X, et al. Among authors: walls m. Mol Cancer Ther. 2017 May;16(5):905-913. doi: 10.1158/1535-7163.MCT-16-0613. Epub 2017 Feb 6. Mol Cancer Ther. 2017. PMID: 28167506
234 results